No Data
Express News | Dupixent® (Dupilumab) Approved in the U.S. as First and Only Treatment for Adolescents With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)
Kiniksa Draws Buy at Jefferies on Potential Blockbuster Status for Lead Drug
Express News | Health Canada Has Issued A Notice Of Compliance For Sanofi/Regeneron Dupixent (Dupilumab Injection) For The Treatment Of Patients Aged 1 Year And Older, Weighing At Least 15 Kg, With Eosinophilic Esophagitis
BMO Capital Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,300
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,230
Sanofi Reports Positive Phase 3 Results for Dupixent for CSU